• BurgoyneDouglas SDSAdjunct associate professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT. Email: burgoyned@gmail.com..
• Adjunct associate professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT. Email: burgoyned@gmail.com.
• Am J Manag Care. 2021 Mar 1; 27 (3 Suppl): S53-S58.

AbstractPulmonary arterial hypertension (PAH) is a rare, progressive disorder associated with a poor prognosis if not treated appropriately. Fortunately, new treatment options have significantly improved survival rates and prognosis. Despite these advances, many patients do not receive the diagnosis until years into their disease or are inappropriately diagnosed. Early referral to specialized treatment centers that allows for early diagnosis and initiation of treatment significantly improves patient outcomes including survival as well as reduction in hospital admissions, which are a main driver of economic burden of disease. It is important that evidence-based guidelines are followed and treatment is individualized based on patient-specific factors. Pharmacologic therapies carry a very high cost for PAH; however, extensive utilization of management strategies may hinder access to medication and may lead to disease progression. Cost containment strategies may help to facilitate care coordination for earlier diagnosis and initiation of treatment, adherence to PAH medications, and patient education to ensure they are using medications appropriately to optimize therapy. Managed care pharmacists can play a crucial role in the multidisciplinary team in terms of medication safety, adherence, patient education, and follow-up to improve patient engagement that leads to improved outcomes.

29 keywords...

hide…